Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature

The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Annalisa, Arcari, Simona, Bassi, Lara, Pochintesta, Elena, Trabacchi, Filippo, Moroni Carlo, Angela, Rossi, Luca, Zanlari, Daniele, Vallisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717301/
https://www.ncbi.nlm.nih.gov/pubmed/29234595
http://dx.doi.org/10.1016/j.lrr.2017.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717301/
https://www.ncbi.nlm.nih.gov/pubmed/29234595
http://dx.doi.org/10.1016/j.lrr.2017.11.001

Ejemplares similares